Announcement for Completion of the PMDA Investigation of CTN (Clinical Trial Notification)for TRG035 Phase IIa Trial.
staff-01Toregem BioPharma Co., Ltd has submitted CTN to PMDA (Pharmaceuticals and Medical Devices Agency) regarding an exploratory clinical trial of an antibody drug (TRG035) for congenital tooth agenesis, and we are pleased to announce that the PMDA has completed the required investigation today 17-Aug-26.
